Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals, Inc. develops, manufactures, and distributes niche generic pharmaceutical products, with product lines focused on immediate-release and controlled-release solid oral dose products. Company news commonly covers FDA approvals for abbreviated new drug applications, commercial launches under the Elite Laboratories label, and licensed distribution relationships with third-party pharmaceutical marketing organizations.
Recurring updates also include quarterly financial results, conference-call announcements, and operating commentary tied to generic product sales. Recent company developments have included methadone hydrochloride tablets, ropinirole extended-release tablets, lisdexamfetamine products, and naltrexone products within Elite's generic drug portfolio.
Elite Pharmaceuticals (OTCQB: ELTP) reported fiscal year 2026 results for the period ended March 31, 2026. Consolidated revenue was $148.9 million, up $64.8 million (~77%) year-over-year. Income from operations reached $49.1 million, an increase of $29.5 million (~151%), driven by Lisdexamfetamine, Oxycodone Acetaminophen, Naltrexone, and Phentermine products.
A conference call is scheduled for June 30, 2026 at 11:30 AM EDT with domestic and international dial-in options and an audio replay link.
Elite Pharmaceuticals (OTCQB: ELTP) will release fiscal year 2026 financial results on Monday, June 29, 2026. Management will host a live conference call on Tuesday, June 30, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update.
Elite Pharmaceuticals (OTCQB: ELTP) reported positive results from a pivotal bioequivalence study for an undisclosed generic anticonvulsant on June 15, 2026. The study showed the generic is bioequivalent to the branded drug under fasting conditions. IQVIA reported combined branded and generic sales of $840 million for the twelve months ending April 2026. Elite is compiling data to file an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration.
Elite Pharmaceuticals (OTCQB: ELTP) submitted an Abbreviated New Drug Application (ANDA) to the U.S. FDA for a generic anticoagulant on June 1, 2026.
According to Elite, the branded reference drug recorded $26 billion in sales for the twelve months ending March 2026 and currently has no generic competitors, but it retains unexpired patents and exclusivities.
Elite Pharmaceuticals (OTCQB: ELTP) announced the commercial launch of its generic methadone hydrochloride tablets in 5 mg and 10 mg strengths on April 2, 2026.
The product targets management of severe persistent pain and opioid detoxification/maintenance. IQVIA data show combined brand and generic annual retail sales of approximately $22 million for 2025.
Elite Pharmaceuticals (OTCQB: ELTP) reported third-quarter fiscal 2026 results for the three months ended December 31, 2025. Revenue was $31.6 million, up about 120% year-over-year. Income from operations was $9.0 million, up ~721%. Net income was $18.6 million.
The company attributed the profit increase primarily to sales of newly launched lisdexamfetamine and naltrexone products plus strong growth in Elite-label lines. Management will host a conference call on February 18, 2026 at 11:30 AM EST to discuss results and recent developments.
Elite Pharmaceuticals (OTCQB: ELTP) will release third quarter fiscal 2026 financial results for the period ended December 31, 2025, on Tuesday, February 17, 2026. Management will host a live conference call on Wednesday, February 18, 2026 at 11:30 AM EST to discuss results and provide a business update.
Dial-in details and a conference number are provided; shareholders are asked to submit general and financial questions by specified deadlines. An audio replay will be available online after the call.
Elite Pharmaceuticals (OTCQB: ELTP) reported results for the second quarter of fiscal 2026 ended September 30, 2025. Consolidated revenue was $36.3 million, up approximately 92% year‑over‑year, and income from operations was $8.2 million, up approximately 136% year‑over‑year. Management attributed the operating improvement primarily to sales of newly launched lisdexamfetamine products and broad growth in Elite‑label product lines. Management will host a conference call on November 17, 2025 at 11:30 AM EST; stockholder financial questions were requested by 7:00 PM EST on November 14, 2025. Financial statements are available on the company Form 10‑Q.
Elite Pharmaceuticals (OTCBB: ELTP) announced FDA approval on November 12, 2025 of an ANDA for a generic version of Requip XL (ropinirole XR) in 2 mg, 4 mg, 6 mg, 8 mg and 12 mg strengths.
The product will be marketed under the Elite Laboratories label. According to IQVIA, the branded product and equivalents had $10 million in U.S. sales for the 12 months ended September 2025, providing a measurable commercial reference for potential generic uptake.
Elite Pharmaceuticals (OTCQB: ELTP) will release its second quarter fiscal 2026 financial results for the period ended September 30, 2025 on Friday, November 14, 2025. Management will host a live conference call on Monday, November 17, 2025 at 11:30 AM EST to review financial and operating results and provide a business update. Stockholders are encouraged to submit questions in advance by the stated deadlines.
Call details: domestic dial-in 1-800-346-7359, international 1-973-528-0008, conference number 98840. Audio replay will be available at https://elite.irpass.com/events_presentations.